Figure 6.
Trough plasma concentrations of MSB11022 and reference adalimumab until week 52. Only patients who consented to take part in a pharmacokinetic substudy provided samples at weeks 14, 15, 25 and 33.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.